TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of death or neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: maximum observed plasma concentration (Cmax) of ATV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration‐time curve (AUC) of ATV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain and stiffness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: period of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial movement improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental status improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of TNM staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion time of the cartoon version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for the cartoon version
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MADRS total score change from baseline to week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge acquisition about asthma and allergies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Responses to sternotomy/sternal spread/maximal sternal spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of contraction relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol‐5D
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Standing one leg eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of 'anxious'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete ablation of thyroid gland remnants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine protective efficacy against all cholera episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaccine protective efficacy against severely dehydrating cholera episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of important clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Terminal elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration between the attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: point prevalence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withdrawal due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: arterial blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stricture recurrence
Endpoint domain: Mortality/survival
Primary endpoint: patient satisfaction degree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total plasma concentration of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patients' compliance and persistence behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Concentration of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satisfaction with subjective quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: responses to clinical safety questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for composite removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite residue left behind
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekend sun-protective behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma aldosterone concentration (PAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Creatinine clearance (CrCl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence and severity of delayed gastric emptying episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hyperglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Temporal resolution and sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rectum maximum dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder maximum dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sigmoid maximum dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death or protocol-specific cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Retinal reattachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Second complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects improving by ≥1 point on the MFVDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum chemerin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shear bond strength of composite resin to dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic remission rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall non-technical skills performance rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client satisfaction with telehealth services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NVP resistance detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and severity of symptoms endorsed on the SERS
Endpoint domain: Adverse events/effects
Primary endpoint: DAS <or= 2.4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical remission (DAS < 1.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response to infliximab as median change in CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in anal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum squeezing pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior anal sphincter length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CG-distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glasgow Results Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroneurography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial TAG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total area under the TAG concentration versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MUC5B release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete elimination of MRSA from the ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hearing acuity evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: population variability of C(SS,trough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall intraoperative product performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retention in the anterior chamber
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: local control of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative difference of ≤3 NIHSS points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean extent of the perfusion defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular perfusion score index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: infarct area perfusion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of at least one PPC
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events (rosacea, hyperpigmentation, hypopigmentation, transient milia)
Endpoint domain: Adverse events/effects
Primary endpoint: VWF:RCo activity by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VWF:RCo/VWF:Ag ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of glucose levels meeting target values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corneal higher-order Strehl ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation transfer function (MTF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sternum wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral ischemia markers (S-100B, NSE, lactate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitussive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expectorant effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anti-asthmatic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decreased appetite ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic success (HIV-1 RNA increase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Excessive Daytime Sleepiness (EDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient self-assessment of sleepiness (Epworth Sleepiness Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of illness (Clinical Global Impression of Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LLIN ownership
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LLIN use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone fracture adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum high sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma total antioxidant capacity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Kansas City Cardiomyopathy Questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in 36-Item Short-Form Health Survey scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: threshold for discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nerve block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rebound pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average loss of haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of the score according to Merle d'Aubigné and Postel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in systolic PAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortening of PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortening of QRS duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: residual beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients using opioids after hospital discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of customers buying promoted products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Product switching from full-fat to low-fat milk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy in obtaining respite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary retention episodes requiring re-catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Uptake of buprenorphine treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of oral health problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG data classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: expected recovery from acute LBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D (6) effect sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of urgent care services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: daily cigarette consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of NK-cell proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of NK cells expressing activation receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude and functionality of ex vivo HCV-specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: amount of weight gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC screening self-efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in perceived lower back pain (LBP) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change of education provided
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Risky drinking amounts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reinfection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of major mishaps
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of minor mishaps
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of all mishaps
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nutritional status (PG-SGA stage A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: development of renal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Drug adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiovascular risk estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in FOG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine pancreatic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of cimetidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite or probable Stent Thrombosis (ST)
Endpoint domain: Mortality/survival
Primary endpoint: faster pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater satisfaction levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in shoulder motion and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average roughness of the skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: TEWL increase after application of the syndet bar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin capacitance decrease after application of the syndet bar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: post-surgery hypocalcemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Dyadic adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Communication improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: freedom from atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Complete recovery rate after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDS death
Endpoint domain: Mortality/survival
Primary endpoint: Total IVH
Endpoint domain: Adverse events/effects
Primary endpoint: Time to response to painful stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aldrete score of 9-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reported flatulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bloating ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Periods of glucose values within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Responder rate (>5% weight loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: z-score composite across the NTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF tau levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anti-HAV seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-HBs seroprotection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: oxytocic augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insertion of intravenous infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal delivery, operative vaginal delivery, caesarean section and complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes